症状性颅内动脉粥样硬化性疾病行颅内外动脉血管融通术的成本效果分析
Cost-Effectiveness Analysis of Encephaloduroarteriosynangiosis Surgery for Symptomatic Intracranial Atherosclerotic Disease.
机构信息
Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Bioscience, University of California, Los Angeles, Los Angeles, California, USA.
出版信息
Neurosurgery. 2022 Apr 1;90(4):495-500. doi: 10.1227/NEU.0000000000001837.
Encephaloduroarteriosynangiosis (EDAS) is a promising treatment for cerebral arterial steno-occlusive disorders, with proven efficacy in moyamoya disease and a growing interest in potential application for patients with symptomatic intracranial atherosclerotic disease, given the early results of intermediate development trials showing reduced rates of recurrence stroke and improved clinical outcomes compared with those patients treated with intense medical management (IMM) alone. Although clinical outcomes are the fundamental goal when considering patient care paradigms, a cost-effective analysis is key to obtaining a comprehensive understanding of the impact EDAS may provide to patients with atherosclerotic disease on a larger scale. Here, we evaluate the EDAS + IMM cost-effectiveness over time in the treatment of intracranial atherosclerotic disease compared with IMM alone.
硬脑膜动脉血管融通术（EDAS）是一种有前途的治疗脑动脉狭窄闭塞性疾病的方法，在烟雾病中已被证明有效，并且由于中间发展试验的早期结果表明，与仅接受强化药物治疗（IMM）的患者相比，复发率降低和临床结局改善，因此对症状性颅内动脉粥样硬化性疾病患者的潜在应用也越来越感兴趣。尽管临床结果是考虑患者护理模式的基本目标，但成本效益分析对于全面了解 EDAS 对更大规模的动脉粥样硬化性疾病患者可能产生的影响至关重要。在这里，我们评估了 EDAS+IMM 与单独 IMM 相比，在治疗颅内动脉粥样硬化性疾病方面的成本效益随时间的变化。
Zotero 插件